Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease

Ustekinumab inhibits interleukins 12 and 23 and modulates the T helper cell-mediated immune response of Crohn's disease. However, ustekinumab may also exacerbate atopic disease by increasing the T helper 2 cell-mediated pathway. We present the first known case of exacerbation of atopic dermatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Andres, Brendan, Taleban, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617006/
https://www.ncbi.nlm.nih.gov/pubmed/36320969
http://dx.doi.org/10.7759/cureus.29718
_version_ 1784820757838168064
author Andres, Brendan
Taleban, Sasha
author_facet Andres, Brendan
Taleban, Sasha
author_sort Andres, Brendan
collection PubMed
description Ustekinumab inhibits interleukins 12 and 23 and modulates the T helper cell-mediated immune response of Crohn's disease. However, ustekinumab may also exacerbate atopic disease by increasing the T helper 2 cell-mediated pathway. We present the first known case of exacerbation of atopic dermatitis in a patient with Crohn's disease receiving ustekinumab. Additional associations in dose frequency, peripheral eosinophilia, and elevated serum IgE were observed. However, while novel in Crohn's disease, exacerbation of atopy after ustekinumab infusion has been observed in patients with psoriasis and psoriatic arthritis.
format Online
Article
Text
id pubmed-9617006
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-96170062022-10-31 Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease Andres, Brendan Taleban, Sasha Cureus Dermatology Ustekinumab inhibits interleukins 12 and 23 and modulates the T helper cell-mediated immune response of Crohn's disease. However, ustekinumab may also exacerbate atopic disease by increasing the T helper 2 cell-mediated pathway. We present the first known case of exacerbation of atopic dermatitis in a patient with Crohn's disease receiving ustekinumab. Additional associations in dose frequency, peripheral eosinophilia, and elevated serum IgE were observed. However, while novel in Crohn's disease, exacerbation of atopy after ustekinumab infusion has been observed in patients with psoriasis and psoriatic arthritis. Cureus 2022-09-28 /pmc/articles/PMC9617006/ /pubmed/36320969 http://dx.doi.org/10.7759/cureus.29718 Text en Copyright © 2022, Andres et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Andres, Brendan
Taleban, Sasha
Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title_full Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title_fullStr Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title_full_unstemmed Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title_short Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
title_sort exacerbation of atopic dermatitis associated with ustekinumab treatment in crohn's disease
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617006/
https://www.ncbi.nlm.nih.gov/pubmed/36320969
http://dx.doi.org/10.7759/cureus.29718
work_keys_str_mv AT andresbrendan exacerbationofatopicdermatitisassociatedwithustekinumabtreatmentincrohnsdisease
AT talebansasha exacerbationofatopicdermatitisassociatedwithustekinumabtreatmentincrohnsdisease

Ejemplares similares